{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2+Positive+Breast+Carcinoma&page=6", "query": { "condition": "HER2 Positive Breast Carcinoma", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 846, "total_pages": 85, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2+Positive+Breast+Carcinoma&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER2+Positive+Breast+Carcinoma&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T20:35:03.328Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01969643", "title": "A Safety Study of SGN-LIV1A in Breast Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2 Positive Breast Neoplasms", "Hormone Receptor Positive Breast Neoplasms", "Triple Negative Breast Neoplasms", "HER2 Mutations Breast Neoplasms" ], "interventions": [ { "name": "ladiratuzumab vedotin", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 290, "start_date": "2013-10-22", "completion_date": "2023-02-04", "has_results": false, "last_update_posted_date": "2023-03-07", "last_synced_at": "2026-10-14T20:35:03.328Z", "location_count": 38, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 30 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01969643" }, { "nct_id": "NCT01953926", "title": "Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations" ], "interventions": [ { "name": "Neratinib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Puma Biotechnology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 582, "start_date": "2013-09-30", "completion_date": "2023-01-02", "has_results": true, "last_update_posted_date": "2024-03-12", "last_synced_at": "2026-10-14T20:35:03.328Z", "location_count": 30, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 26 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01953926" }, { "nct_id": "NCT01423123", "title": "Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" }, { "name": "trastuzumab", "type": "BIOLOGICAL" }, { "name": "Neratinib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "NSABP Foundation Inc", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 21, "start_date": "2011-05", "completion_date": "2014-03", "has_results": false, "last_update_posted_date": "2014-07-08", "last_synced_at": "2026-10-14T20:35:03.328Z", "location_count": 4, "location_summary": "New Brunswick, New Jersey • Pittsburgh, Pennsylvania • Morgantown, West Virginia", "locations": [ { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Morgantown", "state": "West Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01423123" }, { "nct_id": "NCT04246671", "title": "TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chordoma", "HER2-positive Breast Cancer" ], "interventions": [ { "name": "TAEK-VAC-HerBy", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bavarian Nordic", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2020-08-10", "completion_date": "2024-12-11", "has_results": false, "last_update_posted_date": "2025-03-03", "last_synced_at": "2026-10-14T20:35:03.328Z", "location_count": 9, "location_summary": "Scottsdale, Arizona • Santa Monica, California • Jacksonville, Florida + 6 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Santa Monica", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04246671" }, { "nct_id": "NCT00343109", "title": "Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HER2-positive Breast Cancer", "Male Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer" ], "interventions": [ { "name": "HER-2/neu intracellular domain protein", "type": "BIOLOGICAL" }, { "name": "leukapheresis", "type": "PROCEDURE" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "immunologic technique", "type": "OTHER" }, { "name": "synthetic tumor-associated peptide vaccine therapy", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "OTHER" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2004-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2020-02-12", "last_synced_at": "2026-10-14T20:35:03.328Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00343109" }, { "nct_id": "NCT07192432", "title": "Gene Therapy for HER-Positive Cancer (SENTRY-HER2)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HER2 Expressing Solid Tumors" ], "interventions": [ { "name": "Dose Level 1, VNX-202", "type": "GENETIC" }, { "name": "Dose Level 2, VNX-202", "type": "GENETIC" }, { "name": "Dose Level 3, VNX-202", "type": "GENETIC" }, { "name": "Dose Level 4, VNX-202", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Vironexis Biotherapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2025-11-18", "completion_date": "2033-10", "has_results": false, "last_update_posted_date": "2026-07-28", "last_synced_at": "2026-10-14T20:35:03.328Z", "location_count": 11, "location_summary": "Los Angeles, California • Denver, Colorado • Jacksonville, Florida + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT07192432" }, { "nct_id": "NCT05504707", "title": "DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Triple Negative Breast Cancer", "HER2-negative Breast Cancer" ], "interventions": [ { "name": "HER2 - primed Dendritic cells", "type": "BIOLOGICAL" }, { "name": "HER3 - primed Dendritic cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2022-08-26", "completion_date": "2026-10", "has_results": false, "last_update_posted_date": "2026-02-05", "last_synced_at": "2026-10-14T20:35:03.328Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05504707" }, { "nct_id": "NCT07137871", "title": "Clinical Trial of Avasopasem in Patients With Metastatic Hormone Receptor Positive Breast Cancer With Progression on a CDK 4/6 Inhibitor and Hormonal Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer Metastatic" ], "interventions": [ { "name": "Avasopasem", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The University of Texas Health Science Center at San Antonio", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2025-10-02", "completion_date": "2028-10", "has_results": false, "last_update_posted_date": "2025-10-31", "last_synced_at": "2026-10-14T20:35:03.328Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07137871" }, { "nct_id": "NCT02605915", "title": "Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2-Positive Metastatic Breast Cancer", "HER2-Negative Metastatic Breast Cancer", "Locally Advanced or Early Breast Cancer" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Trastuzumab emtansine", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 98, "start_date": "2015-12-31", "completion_date": "2019-11-13", "has_results": false, "last_update_posted_date": "2020-02-05", "last_synced_at": "2026-10-14T20:35:03.328Z", "location_count": 20, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Joliet, Illinois + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Joliet", "state": "Illinois" }, { "city": "Lafayette", "state": "Indiana" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02605915" }, { "nct_id": "NCT02187991", "title": "Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Breast Carcinoma", "Breast Tumors", "Malignant Neoplasm of Breast" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Alisertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "US Oncology Research", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 169, "start_date": "2015-02-12", "completion_date": "2024-08-01", "has_results": true, "last_update_posted_date": "2024-10-09", "last_synced_at": "2026-10-14T20:35:03.328Z", "location_count": 1, "location_summary": "Including Dallas and Austin, Texas", "locations": [ { "city": "Including Dallas and Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02187991" } ] }